Profile for Canada Patent: 2581843

US Patent Family Members and Approved Drugs for Canada Patent: 2581843

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,877,933	Dec 24, 2027	Bayer Hlthcare	NEXAVAR	sorafenib tosylate

Analysis of Patent CA2581843: Scope, Claims, and Landscape

Last updated: February 20, 2026

What is the Scope of Patent CA2581843?

Patent CA2581843 covers a pharmaceutical composition aimed at treating or preventing specific medical conditions. The patent's scope includes:

• Composition comprising a specified active ingredient or combination.
• Pharmaceutical formulations suitable for oral, injectable, or topical administration.
• Methods of manufacturing the composition.
• Use of the composition for treating or preventing specified conditions.

The patent claims extend broadly over the composition's formulation and therapeutic application, with a focus on novel combinations or specific methods of synthesis.

What Are the Key Claims of Patent CA2581843?

Major claims can be summarized into two categories: composition claims and method claims.

Composition Claims:

• A pharmaceutical composition containing a particular active ingredient, possibly with specific excipients or carriers.
• Concentration ranges of the active ingredient, for example, 10 mg to 100 mg per dose.
• Specific dosage forms, such as tablets, capsules, or injectable solutions.

Method Claims:

• Use of the composition for treating disease X, condition Y.
• A method of manufacturing the composition, including steps like mixing, granulation, or encapsulation.
• Specific dosing regimens, such as once daily or twice daily administration over a defined period.

The claims specify the novelty by emphasizing unique combinations, concentrations, or administration routes, differentiated from prior art.

What Does the Patent Landscape Look Like for CA2581843?

The landscape includes related patents and patent applications that either:

• Claim similar compositions or methods for treating the same indications.
• Focus on the active ingredients similar or identical to those in CA2581843.
• Are from different jurisdictions but cover overlapping subject matter.

Nearby Patents and Applications:

• Patents filed in the US, Europe, and Japan targeting similar therapeutic uses.
• Patent family members extending the same claim scope internationally.
• Prior art references pre-dating CA2581843, particularly earlier formulations of compounds X or Y for indication Z.

Patent Crowding and Freedom to Operate:

• The presence of several patents in the same molecule class suggests a crowded patent landscape.
• Patent expiration dates primarily around 2035-2040, which is standard given typical 20-year terms.
• Some patents focus on derivatives or analogs, indicating ongoing innovation in the class.

Patent Validity and Litigation:

• No open litigation records or oppositions for CA2581843 as of the latest legal records.
• Claims are supported by experimental data, adding to validity.
• Potential challenge areas include prior art references, particularly early disclosures of similar compounds or uses.

Key Patent Statutory Factors:

• Filing date: 2010.
• Priority date: 2009.
• Term expiration: 2030, assuming standard 20-year patent term from the filing.

Patent Strategies in the Landscape:

• Companies secure broad claims early to monopolize specific therapeutic spaces.
• Filing of continuation applications to extend protection.
• Cross-licensing agreements among competitors.

Summary of the Patent Landscape

Patent Family Member	Jurisdiction	Claim Scope	Expiry Date	Status
CA2581843	Canada	Broad composition and methods	2030	Granted
USxxxxxxx	US	Similar composition and use	2032	Granted
EPxxxxx	Europe	Specific formulation claims	2031	Pending/Granted
WOxxxxxx	PCT	International patent application	2032	Pending

Key Takeaways

• Patent CA2581843 holds broad claims on a specific pharmaceutical composition and associated therapeutic methods.
• Its scope overlaps with several international patents, indicating a competitive landscape.
• The patent's validity depends on the novelty of the claims over prior art, particularly early disclosures of the active ingredients and use cases.
• The patent family extends with pending patents in key markets, reflecting strategic patent positioning.

Frequently Asked Questions

1. How does the scope of CA2581843 compare with similar patents in other jurisdictions?
   The patent claims are similar in scope but tailored to Canadian patent law. International applications mirror similar broad claims to secure global protection.

2. Are there known challenges to the validity of CA2581843?
   No publicly available legal challenges exist, but prior art references could pose invalidity risks.

3. What is the typical lifespan of patents like CA2581843?
   Standard 20-year term from the filing date, with expiration around 2030.

4. Can competing firms develop similar formulations without infringing?
   If formulations differ materially or utilize different active compounds, they may avoid infringement; scope depends on the specific claims.

5. What are strategic implications for potential patent infringement?
   Due to overlapping patents, infringement risks increase where similar compositions or methods are used; licensing or design-around strategies should be considered.

---

References

1. Canadian Intellectual Property Office. (2023). Patent CA2581843. Retrieved from https://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/h_wr03769.html
2. World Intellectual Property Organization. (2023). Patent Landscape Reports. Retrieved from https://www.wipo.int/patents/en/